

# Research Registries to Accelerate Enrollment in Alzheimer's Trials

**Jessica B. Langbaum, PhD, & Eric M. Reiman, MD**

Alzheimer's Prevention Initiative  
Banner Alzheimer's Institute  
Arizona Alzheimer's Disease Center



If I have seen further, it has been by standing on the shoulders of giants\*



**Jessica Langbaum  
& her Alzheimer's Prevention Registry Team**

*\*Sir Isaac Newton*




## AD Trial Enrollment: The Current US Landscape

- One needs to engage an extraordinary number of people to enroll a sufficient number of eligible participants in AD trials
- AD trials face a narrow, rate-limiting screening & enrollment funnel
  - Need to screen **tens of thousands** to identify the eligible thousands
  - Screen failure rates as high as 85%
- 93% of sites fail to meet their enrollment goal in the originally stated timeline
- 85-90% of all trials (not just AD) experience delays in recruitment & enrollment
- 30% of all trials fail to meet their enrollment goals

## Current Recruiting Models Cannot Supply Enough AD Trial Participants\*

To recruit the estimated 4,500 participants needed in 2016, nearly 7 million people should be contacted



*\*courtesy of GAP Foundation*



## Why a Registry?

- Able to reach thousands of interested individuals for a potential study
- If eligible, able to re-contacted later for a different study
- Potential to accelerate trial enrollment & perhaps enhance retention
- Potential to reduce screen failure rate
- Online registry can complement & enhance local, grassroots recruitment
- Depending on registry's design, may be able to leverage run-in data for trial



## General Public Perceptions about Research Registries

- We analyzed nearly 19,000 conversations from 84 online destinations (websites, blogs, forums, etc.) to try to understand the primary motivators & barriers to join a registry & participate in a trial
  - Drivers: helping future generations, driving science forward, taking control of their own lives
  - Barriers: concerns regarding privacy, data security, who is “behind” the program
- Meantime, we continue to learn from API & other programs about factors that influence a registry participant’s willingness to participate in a trial
  - e.g., their proximity to a trial site



## Recruitment Registries: Examples in the US\*

### • National Registries

- Alzheimer's Prevention Registry
- Brain Health Registry
- DIAN Expanded Registry
- GeneMatch
- HealthyBrains
- ResearchMatch
- TrialMatch

### • Local / Regional Registries


- Butler Alzheimer's Prevention Registry
- Penn Memory Center Brain Health Research Registry
- Rhode Island AD Prevention Registry
- UC Irvine Consent-to-Contact Registry
- Wisconsin ADRC Registry

## Tiers of Engagement in Several National Registries

Requirements / Engagement Tiers	Alzheimer's Prevention Registry	Brain Health Registry	GeneMatch	TrialMatch
consent / create account		X	X	X
contact information	X	X	X	X
demographic information	X	X	X	X
study opportunity notifications	X	X	X	one-time match continuous match TBD
cognitive testing every 6 mos		X		
study partner Enrollment		optional		
DNA APOE tests			X	
DNA multiple genetic tests		GenePool substudy		
DNA storage for future tests		GenePool substudy		



# Recruitment Registry Example: the Alzheimer's Prevention Registry




The screenshot shows the Alzheimer's Prevention Registry website. The header includes the logo, "HOSTED BY BANNER ALZHEIMER'S INSTITUTE", and navigation links: Home, About Us, For Researchers, Contact Us, News, and SPREAD THE WORD. Below the header are links for Why Join, Find a Study, Alzheimer's Prevention 101, About the Registry, and GeneMatch.

The main content area is split into two columns. The left column, titled "WHY NOW?", lists three steps: 1. Sign Up to help end Alzheimer's, 2. Receive Emails about prevention study opportunities and research news, and 3. Participate in studies you choose and qualify for. The right column, titled "THE ALZHEIMER'S PREVENTION REGISTRY IS A PARTNERSHIP OF:", features a large number "341,534" and the text "people have signed up to help end Alzheimer's. THE NEXT STEP IS YOURS." Below this is a sign-up form with fields for E-mail \*, First Name \*, Last Name \*, United States (dropdown), Zip/Postal Code \*, and Year of Birth \*. A pink "SIGN UP NOW" button is at the bottom, along with a link for "Already Registered?". A privacy notice at the bottom states: "Your privacy is extremely important! We promise to protect it - [learn more](#)".

- Began with API's interest in enrolling cognitively unimpaired APOE4 homozygotes in a prevention trial
- Currently helping to recruit for 39 studies, primarily in US
- Offers several email subscriptions services: monthly newsletter, community events, study opportunities
- ~86,000 adults age 60+ receive our emails
- highly engaged, average 30-40% email open rates
- not representative of US population, predominately white women (focus of pending R01 grant)

## Recruitment Registry Example: GeneMatch

- GeneMatch has enrolled >90,000 cognitively healthy 55-75 year olds in the US
- CLIA-certified APOE genotypes in >62,000



- GeneMatch as a US recruitment resource for the API Generation Program

# of Referrals to Generation	# of participants who have opened the invitation	# of participants who have accepted the invitation	# of participants who have declined the invitation	Referrals contacted by site
14,455	9,771	4,705	246	4,299



## API Colombia Registry

- Led by Francisco Lopera & his Grupo Neurosciences de Antioquia (GNA) in partnership with API
- Includes more than >5,800 persons, 8-75 years of age, from the largest ADAD kindred, including ~1200 *PSEN1 E280A* mutation carriers--& 6 homozygotes
  - e.g., plasma NfL study in more than 1,100 carriers & 1,100 age & sex-matched non-carriers.
- Blood samples & genetic testing in all; clinical & cognitive assessments in most
- Sole recruitment mechanism for the API ADAD Colombia Trial
- Supports observational, genetic, brain imaging, fluid biomarker & neuropathological studies
- Potential to extend to other autosomal dominant AD & CADASIL kindreds
- Foundation for other observational, biomarker, treatment & prevention studies



## Future Direction: Amyloid Blood Test Screening Program

- Building off the GeneMatch model, we have been exploring the development of an A $\beta$  blood test screening program
  - To accelerate & improve the efficiency of enrolling A $\beta$ + participants (including APOE4 non-carriers) in prevention trials
  - To provide a resource of blood samples & brain imaging data for the further evaluation of different A $\beta$  tests (including a subset of persons who with a negative blood test)
  - To provide a foundation for the potential use of A $\beta$  blood tests as a screening tool in the clinical setting



## Challenges to the development of recruitment registries – The tip of the iceberg!

- Even if you build it, they may not come! Requires considerable advertising & outreach to enroll participants
  - Attracting healthy people
  - Limited diversity. Most respondents are white, educated & female (though some can be gate-keepers for other eligible participants)
- One size does not fit all: best practices are limited in terms of their generalizability
  - How much data do you collect at signup? Different thresholds of commitment at entry yield different populations & results
- Requires a high level of customer service & continued engagement with enrollees
  - To date, most registries are only in English
- Navigating a complicated regulatory / legal landscape to...
  - Collect personally identifiable information (PII) & protected health information (PHI)
  - Connect people to studies & provide metrics of study enrollment success
  - Collect DNA & perform genetic tests
- Funding
  - NIH does not support “infrastructure” for registries, but supports cohort studies
- Creating the IT infrastructure is time consuming & expensive
  - No “out of the box” solution
- Website design matters



## Future Directions

- Gain a deeper understanding of motivators & barriers
  - particularly for under-represented racial, ethnic & male groups
- Monitor & continue to optimize our registries' performance & impact
  - including their impact on study engagement, enrollment, & retention
- Partner with Ethics Committees / IRBs:
  - work towards using more motivational, inspirational language to encourage enrollment, particularly for healthy adults & under-represented groups
  - find seamless mechanisms to share participant PII/PHI
- Incorporate new features & technologies to online registries to promote engagement, retention & data collection
  - e.g., text messaging, wearable technologies, etc
- Translate registries to other languages
  - Would require multilingual staff for registries, study sites
  - Not just the websites, but also all retention/engagement emails, etc
- Work with & support other registries
- Challenge: How to extend to other countries
  - For instance, how to address European Union Global Data Protection Requirements (GDPR) & other regulatory & language requirements



# Acknowledgements

## **National Institute on Aging**

RF1 AG041705, UF1 AG046150, R01 AG031581, R01 AG055444, R01 AG068468, P30 AG19610

## **State of Arizona**

Arizona Alzheimer's Consortium

## **Industry**

Genentech/Roche & Novartis/Amgen

## **Foundations**

Banner Alzheimer's Foundation, NOMIS Foundation, Anonymous Organizations,  
Flinn Foundation, GHR Foundation, Alzheimer's Association

## **Our Alzheimer's Prevention Registry Team**

Nellie High, Jodie Nichols, Cassandra Kettenhoven & Hayley Graf

## **Our colleagues, collaborators, supporters & valued research participants**

Pierre Tariot & our API colleagues, collaborators & advisors

Francisco Lopera, Silvia Rios & our University of Antioquia & Colombian API Registry colleagues